Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease (Q38252870)

1 September 2017

1 reference

title

Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

1 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sebastian L Johnston

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

3

Aran Singanayagam

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

6

Patrick Mallia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Matthew Berry

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sarah L Elkin

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

17 September 2014

1 reference

The Lancet. Respiratory medicine

1 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

919-932

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

1 reference

7 January 2021

Chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Reported pneumonia in patients with COPD: findings from the INSPIRE study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled corticosteroids in COPD and the risk of serious pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled drugs as risk factors for community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

The natural history of community-acquired pneumonia in COPD patients: a population database analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

COPD is associated with increased mortality in patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary d

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Predictors of outcomes in COPD exacerbation cases presenting to the emergency department.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Diagnosis of ambulatory community-acquired pneumonia. Comparison of clinical assessment versus chest X-ray.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Diagnosing pneumonia in patients with acute cough: clinical judgment compared to chest radiography

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

International classification of diseases codes showed modest sensitivity for detecting community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Risk factors for community-acquired pneumonia in adults in Europe: a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Efficacy of Antibiotic Therapy for Acute Exacerbations of Mild to Moderate Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Budesonide and risk of pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Incidence and characteristics of viral community-acquired pneumonia in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Thin-section CT findings of patients with acute Streptococcus pneumoniae pneumonia with and without concurrent infection.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Distribution of T-cell subsets in BAL fluid of patients with mild to moderate COPD depends on current smoking status and not airway obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Defective macrophage phagocytosis of bacteria in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Prolonged airway activity and improved selectivity of budesonide possibly due to esterification.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Chronic Exposure to Glucocorticoids Shapes Gene Expression and Modulates Innate and Adaptive Activation Pathways in Macrophages with Distinct Changes in Leukocyte Attraction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferón)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Phagocytosis and oxidative burst of blood phagocytes in chronic obstructive airway disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Attenuated translocation of group IVa phospholipase A2 and up-regulated annexin-1 synthesis by glucocorticoid blocks beta 2-integrin adhesion in neutrophils.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Reduced glucocorticoid receptor expression and function in airway neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Beta2-agonists potentiate corticosteroid-induced neutrophil survival

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Budesonide suppresses pulmonary antibacterial host defense by down-regulating cathelicidin-related antimicrobial peptide in allergic inflammation mice and in lung epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Fluticasone propionate reduces bacterial airway epithelial invasion

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Inhaled corticosteroids increase the risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Corticosteroids directly reduce Staphylococcus aureus biofilm growth: an in vitro study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Effect of bronchial colonisation on airway and systemic inflammation in stable COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Analysis of the lung microbiome in the "healthy" smoker and in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

The lung tissue microbiome in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Disordered microbial communities in asthmatic airways

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

The lung microbiome in moderate and severe chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Impact of preceding respiratory viral infections on the clinical severity of patients with pneumococcal pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Number needed to treat in COPD: exacerbations versus pneumonias

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

Vitamin D status and community-acquired pneumonia: results from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

The coordination of breathing and swallowing in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970169-9

7 January 2021

10.1016/S2213-2600(14)70169-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25240963%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference